Soligenix granted pediatric investigational plan waiver for hybryte™ in ctcl in the united kingdom

Princeton, n.j., nov. 8, 2021 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has been granted a pediatric investigation plan (pip) product-specific waiver from the medicines and healthcare products regulatory agency (mhra) for hybryte™ (sgx301 or synthetic hypericin), which has successfully concluded a phase 3 pivotal clinical study for the treatment of early stage cutaneous t-cell lymphoma (ctcl).
SNGX Ratings Summary
SNGX Quant Ranking